IL17RA and psoriasis vulgaris: For reference, the ProLOGUE study—an open-label, multicenter, real-world randomized study in Japanese adults with plaque psoriasis treated with the IL-17RA inhibitor brodalumab via subcutaneous injection—reported a TSQM-9 satisfaction score of 83% [55].